Metastatic breast cancer | Â |
 No. of patients enrolled—100 |  |
 Age, years |  Hormone receptor status |
  Median, range 59 (66–81) |   ER-positive/PR-positive—45 (45%) |
 ECOG performance status |   ER-positive/PR-negative—16 (16%) |
 |   ER-negative/PR-positive—5 (5%) |
  0—66 (66%) |   ER-negative/PR-negative—18 (18%) |
  1—23 (23%) |   Unknown—16 (16%) |
  2—6 (6%) |  No. of disease sites |
  Unknown—5 (5%) |   1—51 (51%) |
 Histology |   2—21 (21%) |
  Ductal—75(75%) |   3—11 (11%) |
  Lobular—10 (10%) |   ≥ 4—2 (2%) |
  Other—9(9%) |   Unknown—15 (15%) |
  Unknown—6 (6%) |  Visceral disease |
 Menopausal status |   Yes—37 (37%) |
  Premenopausal—26 (26%) |   No—50 (50%) |
  Perimenopausal—12 (12%) |   Unknown—13 (13%) |
  Postmenopausal—53 (53%) |  Triple negative (ER negPRnegHER2neg) |
  Unknown—9 (9%) |   11 (11%) |
 HER2 status |  |
  HER2 negative—64 (64%) |  |
  Her2 positive—18 (18%) |  |
  Unknown—18 (18%) |  |